neutropenia


Naproxen May Relieve Bone Pain Associated with Neulasta (August 2, 2012)

Twice-daily naproxen is effective in reducing the incidence and severity of bone pain associated with the use of Neulasta® (pegfilgrastim), according to the results of a study published in the Journal... Continue Reading

Chemotherapy for Older Patients: What You Should Know About the Risk of Infection (June 3, 2012)

As you may already know, chemotherapy works by attacking the rapidly dividing cells it finds in the body, particularly cancer cells because they multiply quickly. However, chemotherapy can’t differentiate... Continue Reading

It’s Not Just a Little Fever: Preventing Infection during Therapy for Lymphoma (October 30, 2010)

Many cancer patients are at an increased risk of infection because of their low levels of infection-fighting white blood cells, a condition called neutropenia. The most common reason that cancer patients... Continue Reading

Patient Action to Prevent Infection During Treatment for Cancer (February 11, 2010)

Most patients would prefer to prevent infection rather than having to deal with its results. Your first line of defense should always be prevention. Below are some simple but effective steps to avoid infection: Always... Continue Reading

Conquering Chemotherapy-How advances in the management of neutropenia have led to advances in curative therapy. (February 10, 2010)

By Maria G. Essig, MS, ELS If you were to ask the average person—even the most health conscious of your friends—what their neutrophil count is, chances are you would get a blank stare. But as a cancer... Continue Reading

Successful Treatment Means Staying on Schedule (December 2, 2009)

In order to receive the best possible benefit from your cancer therapy, it is important to follow your treatment as your doctor has prescribed. Even if you’re not able to visit your regular treatment... Continue Reading

Dose Intensity Associated with Survival in Non-Hodgkin’s Lymphoma (September 9, 2008)

Relative dose intensity (RDI) remains a key factor in the outcomes of patients with non-Hodgkins lymphoma (NHL). These results have been validated in several multicenter clinical studies. Non-Hodgkin’s... Continue Reading

Neulasta® Deemed Cost-effective for Prevention of Febrile Neutropenia in Breast Cancer Patients (August 15, 2008)

The prophylactic use of Neulasta® (pegfilgrastim) is cost-effective for the prevention of febrile neutropenia in patients undergoing treatment for breast cancer. The details of this study appeared in... Continue Reading

Early Use of Neulasta® Superior to Later Use In Elderly Patients Undergoing Chemotherapy (August 8, 2008)

The use of Neulasta® (pegfilgrastim) after the first cycle of chemotherapy among elderly patients undergoing chemotherapy decreases febrile neutropenia and associated effects compared with its use later... Continue Reading

Prophylactic Neulasta® Reduces Febrile Neutropenia and Early Deaths Among Patients Receiving Chemotherapy (July 31, 2008)

Prophylactic use of Neulasta® (pegfilgrastim) among cancer patients receiving chemotherapy reduces the risk of developing febrile neutropenia and early death. These results were recently published in... Continue Reading

Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (March 17, 2008)

The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day... Continue Reading

Neulasta® Reduces Hospitalizations for Febrile Neutropenia in Women with Breast Cancer (October 2, 2007)

According to results presented at the European Cancer Conference (ECCO 14), preventive treatment with Neulasta® (pegfilgastim) improved chemotherapy delivery and reduced the risk of febrile neutropenia... Continue Reading

Neulasta® Reduces Risk of Neutropenia in Colorectal Cancer Patients (August 10, 2007)

According to the results of a study presented at the 9th World Congress on Gastrointestinal Cancer, Neulasta® (pegfilgrastim) reduces the risk of severe neutropenia (low white blood cell count) in colorectal... Continue Reading

Preventive Treatment Reduces Risk of Febrile Neutropenia and Early Death (August 3, 2007)

According to the results of a study published in the Journal of Clinical Oncology, preventive treatment with a granulocyte colony stimulating factor (drugs that boost white blood cell levels) reduces the... Continue Reading

Early Use of Neulasta Reduces Complications from Neutropenia in Non-Hodgkin’s and Hodgkin’s Lymphomas (January 5, 2007)

According to results recently presented at the 2006 annual meeting of the American Society of Hematology, the use of Neulasta® (pegfilgrastim) during the first courses of chemotherapy significantly reduces... Continue Reading

Neulasta® Safe and Effective for Hodgkin’s Patients Treated with ABVD Chemotherapy (November 7, 2006)

Among Hodgkin’s lymphoma patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy every two weeks, use of Neulasta® (pegfilgrastim) was safe and allowed most... Continue Reading

Guidelines Address Prevention of Neutropenia (July 13, 2006)

According to updated recommendations from the American Society of Clinical Oncology, use of blood cell growth factors to prevent febrile neutropenia is warranted when risk of febrile neutropenia is 20%... Continue Reading

Fewer Complications Related to Low White Blood Cell Counts Among Patients Treated with Neulasta® in the First Cycle of Chemotherapy (June 7, 2006)

According to the final results of a large clinical trial, giving Neulasta® (pegfilgrastim) to patients undergoing chemotherapy reduces their risk of complications related to low white blood cell counts... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS